Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Neil H. Segal, José Saro, Ignacio Melero, Willeke Ros, G. Argiles, Aurélien Marabelle, Marta Ester Ruíz, Joan Albanell, Emiliano Calvo, Víctor Moreno,

Annals of Oncology

Single AgentMedicineImmunologyColorectal CancerMetastatic Colorectal CancerImmune Checkpoint InhibitorCea-cd3 TcbImmunotherapyOncologyRadiation Oncology